NASDAQ:DMAA • KYG2847J1040
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DRUGS MADE IN AMERICA ACQUIS (DMAA).
| 2023 | 2024 | ||
|---|---|---|---|
| Revenue YoY % growth | |||
| EBITDA YoY % growth | N/A | N/A | |
| EBIT YoY % growth | -279.9K | ||
| Operating Margin | N/A | N/A | |
| EPS YoY % growth | N/A | N/A |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
DRUGS MADE IN AMERICA ACQUIS (DMAA) will report earnings on 2026-03-18.